Effect of acidification on protein binding of mycophenolic acid [3]

Therapeutic Drug Monitoring

Volumn 29, Issue 1, 2007, Pages 132-133

  Ting, Lillian S L ^a   Decarie, Diane ^b   Ensom, Mary H H ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; MYCOPHENOLIC ACID;

ACIDIFICATION; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG MONITORING; EXPERIMENTAL STUDY; GRAFT RECIPIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETTER; MOLECULAR WEIGHT; PLASMA; PRIORITY JOURNAL; PROTEIN BINDING;

ANTIBIOTICS, ANTINEOPLASTIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; HUMANS; HYDROGEN-ION CONCENTRATION; MYCOPHENOLIC ACID; PHOSPHORIC ACIDS; PROTEIN BINDING; RESEARCH DESIGN;

EID: 33847118650     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000255011.75863.15     Document Type: Letter

References (21)

1. Shaw LM, Korecka M, DeNofrio D, et al. Pharmacokinetic, pharmacodynamic and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem. 2001;34:17-22.
2. Shaw LM, Holt DW, Oellerich MO, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001;23:305-315.
3. Pillans PI, Rigby RJ, Kubler P, et al. A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients. Clin Biochem. 2001;34:77-81.
4. Krumme B, Wollenberg K, Kirste G, et al. Drug monitoring of mycophenolic acid in the early period after renal transplantation. Transplant Proc. 1998;30:1773-1774.
5. Ensom MH, Partovi N, Decarie D, et al. Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. Ther Drug Monit. 2002;24:310-314.
6. Ensom MH, Partovi N, Decarie D, et al. Mycophenolate pharmacokinetics in early period following lung or heart transplantation. Ann Pharmacother. 2003;37:1761-1767.
7. Ting LS, Partovi N, Levy RD, et al. Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients. Ann Pharmacother. 2006;40:1509-1516.
8. Shaw LM, Nawrocki A, Korecka M, et al. Using established immunosuppressive therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations. Ther Drug Monit. 2004;26:347-351.
9. Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant. 2003;3:534-542.
10. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672-683.
11. Schutz E, Shipkova M, Armstrong VW, et al. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem. 1999;45:419-422.
12. Wieland E, Shipkova, Shellhaas U, et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem. 2000;33:107-113.
13. Shipkova M, Wieland E, Schutz E, et al. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc. 2001;33:1080-1081.
14. Kuypers DR, Vanrenterghem Y, Squifflet JP, et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit. 2003;25:609-622.
15. Shipkova M, Schutz E, Armstrong VW, et al. Determination of the acyl glucuronide metabolite ofmycophenolic acid in human plasma by HPLC and Emit. Clin Chem. 2000;46:365-372.
16. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. J Am Soc Nephrol. 1998;9:1511-1520.
17. Shipkova M, Niedmann PD, Armstrong VW, et al. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem. 1998;44:1481-1483.
18. Cattaneo D, Gaspari F, Ferrari S, et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant. 2001;15:402-409.
19. Atcheson BA, Taylor PJ, Kirkpatrick CM, et al. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit. 2004;26:284-286.
20. Shipkova M, Armstrong VW, Oellerich M, et al. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit. 2003;25:1-16.
21. Roche Laboratory, Inc. Cellcept (mycophenolate mofetil) Drug Monograph. Nutley, NJ: Roche Laboratory, 2003.